This study is for women aged 65 and older with early-stage, estrogen receptor-positive (ER+), HER2-negative breast cancer. It aims to see if giving endocrine therapy (like Tamoxifen, Letrozole, Anastrozole, or Exemestane) before surgery can help decide if radiation therapy (RT) is needed. You would either receive 3 months of this endocrine therapy before breast cancer surgery, or go straight to surgery as is standard. Researchers will look at how many participants skip radiation therapy but don't stick with their endocrine therapy, and how many receive surgery, radiation, and endocrine therapy, both measured at 24 months. The goal is to understand if this pre-surgery treatment can help avoid unnecessary radiation or ensure patients who skip radiation can tolerate their endocrine therapy.

Study design

This is a Phase III, multisite exploratory study with 354 participants. You would be randomly assigned to one of two groups: either receiving 3 months of pre-operative endocrine therapy or going directly to surgery.

What's involved

You would either take endocrine therapy for 3 months before surgery or proceed directly to breast cancer surgery. Both groups will complete patient surveys to assess tolerance and compliance with endocrine therapy.

Compensation

Not stated in the trial record.

Follow-up

Researchers will follow participants for 24 months after treatment to measure the main study outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.